Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
Meningococcal vaccines protect against bacterial meningitis — a rare but potentially fatal infection. Routinely given to adolescents at ages 11-12 and 16, and required by many colleges for dorm residents. VAERS contains over 36,000 reports across all meningococcal vaccine types.
The following symptoms are most frequently reported after meningococcal vaccination:
There are two main categories:
MenB vaccines tend to have more local side effects (injection site pain) than MenACWY vaccines, which is reflected in VAERS reporting patterns.
Very common:
Common:
Rare:
A notable portion of meningococcal vaccine VAERS reports involve syncope (fainting). This is not specific to meningococcal vaccines — adolescents faint after any injection at much higher rates than other age groups. The CDC recommends a 15-minute observation period after vaccinating adolescents for this reason.
Meningococcal disease is rare (about 300-400 cases/year in the U.S.) but devastating — 10-15% of cases are fatal, and up to 20% of survivors have permanent complications like limb amputation, hearing loss, or brain damage. The vaccine has dramatically reduced cases in the age groups most at risk.
MenACWY is routine at ages 11-12 with a booster at 16. See where meningococcal vaccines fit on the CDC vaccine schedule and our 2026 vaccine schedule analysis.
As of mid-2026, the meningococcal vaccine continues to be monitored through VAERS and complementary surveillance systems including the Vaccine Safety Datalink (VSD) and the Clinical Immunization Safety Assessment (CISA) project. No new safety signals have been identified in recent data that would change the established safety profile of this vaccine.
The HHS administration's announced development of AI-powered VAERS analysis tools may provide additional insights into meningococcal vaccine adverse event patterns. These tools aim to detect subtle signals that traditional statistical methods might miss, though their implementation timeline and methodology remain under development.
It's worth noting that VAERS reporting for routine vaccines like meningococcal has remained stable through the post-pandemic period. While COVID-19 vaccine reports surged and then declined, reporting patterns for established childhood and adult vaccines have been remarkably consistent, suggesting that the VAERS system continues to function as designed for ongoing safety surveillance.
When interpreting VAERS data for meningococcal vaccines, several key principles apply:
VAERS data is most useful as a starting point for conversation with your healthcare provider, not as a basis for medical decisions. If you're concerned about meningococcal vaccine side effects:
For the most up-to-date safety information, consult the CDC's vaccine information pages or speak with a qualified healthcare professional.
As of mid-2026, the meningococcal vaccine continues to be monitored through VAERS and complementary surveillance systems including the Vaccine Safety Datalink (VSD) and the Clinical Immunization Safety Assessment (CISA) project. No new safety signals have been identified in recent data that would change the established safety profile of this vaccine.
The HHS administration's announced development of AI-powered VAERS analysis tools may provide additional insights into meningococcal vaccine adverse event patterns. These tools aim to detect subtle signals that traditional statistical methods might miss, though their implementation timeline and methodology remain under development.
It's worth noting that VAERS reporting for routine vaccines like meningococcal has remained stable through the post-pandemic period. While COVID-19 vaccine reports surged and then declined, reporting patterns for established childhood and adult vaccines have been remarkably consistent, suggesting that the VAERS system continues to function as designed for ongoing safety surveillance.
When interpreting VAERS data for meningococcal vaccines, several key principles apply:
VAERS data is most useful as a starting point for conversation with your healthcare provider, not as a basis for medical decisions. If you're concerned about meningococcal vaccine side effects:
For the most up-to-date safety information, consult the CDC's vaccine information pages or speak with a qualified healthcare professional.